Jan 28, 2011 by Brian Orelli, PhDLooking Ahead at Bristol-MyersProduct approvals now will help with the patent cliff.
Jan 27, 2011 by Brian Orelli, PhDGilead's Once in a Decade QuarterGilead's revenue falls for the first time in more than a decade.
Jan 27, 2011 by Brian Orelli, PhDAmylin Timeline Shortened -- MaybeA little clarity, but just a little.
Jan 27, 2011 by Brian Orelli, PhDAbbott Labs: Growth in All the Wrong PlacesAbbott is growing, but investors are rightfully worried.
Jan 27, 2011 by Brian Orelli, PhDThe Multibillion-Dollar Fight Over a DefinitionThis is big business for brand and generic drugmakers.
Jan 27, 2011 by Brian Orelli, PhDYour CEO Isn't Qualified to Run a Drug CompanyOr so says George Scangos.
Jan 26, 2011 by Brian Orelli, PhDHealth-Care Reform Lives: Here's Where to InvestState of the Union turned investment thesis.
Jan 25, 2011 by Brian Orelli, PhD2 Keys to Amgen's Continued SuccessProlia and Xgeva have to perform.
Jan 25, 2011 by Brian Orelli, PhDSo Really, How Close Are You to an Approval?Momenta's shareholders really want to know.
Jan 25, 2011 by Brian Orelli, PhDFDA Approved -- Now Will It Sell?There's still plenty of uncertainty in Clinical Data's shares.
Jan 21, 2011 by Brian Orelli, PhDThe Obese Queue of UnknownsVIVUS' resubmission will take longer than expected.
Jan 19, 2011 by Brian Orelli, PhDHigh Stakes at Tomorrow's FDA Panel MeetingIt's more than just Eli Lilly on the line.
